CSIMarket Company Name, Ticker, Competitors, else..
 
Incannex Healthcare Inc  (NASDAQ: IXHL)
 
Price: $3.2300 $-0.02 -0.615%
Day's High: $3.3164000511169434 Week Perf: -0.46 %
Day's Low: $ 3.20 30 Day Perf: 1.89 %
Volume (M): 27,285 52 Wk High: $ 20.31
Volume (M$): $ 0 52 Wk Avg: $7.11
Open: $3.25 52 Wk Low: $2.49



 Market Capitalization (Millions $) 40
 Shares Outstanding (Millions) 12
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 60
 Capital Exp. (TTM) (Millions $) 0

Business Description


Incannex Heal is a pharmaceutical company involved in the development of drug candidates, including IHL-42X, PSX-001, and IHL-675A. The company conducts research and development activities, including clinical testing and manufacturing, with the objective of obtaining regulatory approvals and commercializing its drug candidates.


   Company Address: Suite 105 NSW 2153
   Company Phone Number: 409 840 786   Stock Exchange / Ticker: NASDAQ IXHL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.43%    
BMY   -6.83%    
ETST        12.5% 
LIFD      0% 
LLY   -3.53%    
PFE   -4.46%    
• View Complete Report
   



Financing Agreement

Incannex Healthcare Secures Strategic Financing for Growth: Up to $60 Million from Arena Investorsnn

Published Tue, Sep 10 2024 12:00 PM UTC


In the fast-evolving landscape of biotech and pharmaceuticals, securing adequate funding is often the linchpin for advancing innovative therapies and sustaining growth. Recently, Incannex Healthcare, a company focused on the development of therapies utilizing psychedelic compounds, announced a significant strategic financing agreement that could reshape its financial tr...
Clinical Study

In an exciting development for the field of psychiatric and psychedelic-assisted therapies, Inc...

Published Mon, Aug 5 2024 11:30 AM UTC

FDA Approves Incannex Healthcare’s Phase 2 Clinical Trial for Psilocybin-Assisted Psychotherapy in Generalized Anxiety Disorder Patients In an exciting development for the field of psychiatric and psychedelic-assisted therapies, Incannex Healthcare Inc. (Nasdaq: IXHL) has received approval from the US Food and Drug Administration (FDA) to proceed with an Investigational ...
Clinical Study

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug ca...

Published Tue, Jul 30 2024 11:30 AM UTC

Incannex Healthcare Advances Novel Therapeutics for Sleep Apnea and Rheumatoid Arthritis: Completion of Dosing in Bioavailability Trial and Launch of Phase 2 Study for IHL-675A Incannex Healthcare Inc., a clinical-stage pharmaceutical company at the forefront of developing innovative medicinal cannabinoid products and psychedelic-assisted therapies, has made significant st...
Clinical Study

Revolutionizing Sleep Therapy: Innovative Drug IHL-42X Holds Promise for Treating Obstr...

Published Thu, May 30 2024 11:30 AM UTC

Patient Dosing Commenced in RePOSA Phase 2/3 Clinical Trial to Evaluate the Efficacy of IHL-42X Drug in Patients with Obstructive Sleep ApneaObstructive Sleep Apnea (OSA) is a common sleep disorder that affects millions of people worldwide. It is characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to disrupted breat...
Product Service News

Incannex Receives FDA Nod to Advance CannQuit-O as Innovative Therapy for Opioid Addiction

Published Tue, May 7 2024 11:30 AM UTC

In a significant step forward in the battle against the opioid epidemic, Incannex Healthcare Inc., a leading cannabinoid and psychedelic medicine biotechnology company, has successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). The meeting s was to gain FDA approval for the development of CannQuit-O, a potential...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 463.79
Price to Sales (Expected) -
Price to Book 0.53
PEG (TTM) -

Financial Strength Current
Quick Ratio 38.64
Working Capital Ratio 41.56
Leverage Ratio (MRQ) 0.07
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) 818841.75

Per Share Current
Earnings (TTM) -34.66 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 4.89 $
Cash 6.03 $
Book Value 6.09 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,204,938
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.